Project description:This SuperSeries is composed of the following subset Series: GSE36324: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-HCC1954] GSE36325: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-Longterm] GSE36326: Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-SKBR3] Refer to individual Series
Project description:Targeted inhibition of human breast cancer cell line selected as model system of ERBB2-positive breast cancer [RPPA-Shortterm-BT474]
Project description:Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-Longterm]
Project description:Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-Longterm-HCC1954-SKBR3]
Project description:Targeted inhibition of human breast cancer cell line selected as model system of ERBB2-positive/EGFR high breast cancer [RPPA-Shortterm-SKBR3]
Project description:Targeted inhibition of human breast cancer cell line selected as model system of ERBB2-positive/EGFR high breast cancer [RPPA-Shortterm-HCC1954]
Project description:Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-SKBR3]
Project description:Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-HCC1954]
Project description:EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR.
Project description:EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer. Approximately 30% of human ERBB2-positive breast tumors also express EGFR.
